Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 20/20 | 0.68 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.62 |
| ▸ | RORA | P35398 | 1/20 | 0.62 |
| ▸ | RORB | Q92753 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29170638 | 1.00 | RORC (0.68) | RORCNR1I2RORARORB | |
| SCHEMBL22278646 | 0.94 | RORC (0.66) | RORCNR1I2RORARORB | |
| SCHEMBL29118058 | 0.94 | RORC (0.66) | RORCNR1I2RORARORB | |
| SCHEMBL22278443 | 0.94 | RORC (0.65) | RORCNR1I2RORARORB | |
| SCHEMBL23102381 | 0.92 | RORC (0.63) | RORCNR1I2RORARORB | |
| SCHEMBL30816105 | 0.92 | RORC (0.63) | RORCNR1I2RORARORB | |
| SCHEMBL30816183 | 0.92 | RORC (0.69) | RORCNR1I2RORARORB | |
| SCHEMBL23093707 | 0.92 | RORC (0.69) | RORCNR1I2RORARORB | |
| SCHEMBL22278740 | 0.91 | RORC (0.62) | RORCNR1I2RORARORB | |
| SCHEMBL22278651 | 0.91 | RORC (0.62) | RORCNR1I2RORARORB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114096533-B | Tri-ring compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-114096533-A | Tricyclic compound, pharmaceutical composition containing same, preparation method and application thereof | 四川科伦博泰生物医药股份有限公司 | 2022-02-25 | — | — | CN | disclosed |